Evidence map›Paper›PMID 26846189›Full record

ArticleNanoscale2016

Ultratrace level determination and quantitative analysis of kidney injury biomarkers in patient samples attained by zinc oxide nanorods.

Manpreet Singh, Anginelle Alabanza, Lorelis E Gonzalez, Weiwei Wang, W Brian Reeves, Jong-in Hahm

Abstract read
In one paragraph

Article in Nanoscale, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Manpreet SinghDepartment of Chemistry, Georgetown University, 37th & O Sts. NW., Washington, DC 20057, USA. jh583@georgetown.edu.
Anginelle AlabanzaDepartment of Chemistry, Georgetown University, 37th & O Sts. NW., Washington, DC 20057, USA. jh583@georgetown.edu.
Lorelis E GonzalezDepartment of Chemistry, Georgetown University, 37th & O Sts. NW., Washington, DC 20057, USA. jh583@georgetown.edu.
Weiwei WangDivision of Nephrology, The Penn State College of Medicine, Milton S. Hershey Medical Center, Hershey, Pennsylvania 17033, USA.
W Brian ReevesDivision of Nephrology, The Penn State College of Medicine, Milton S. Hershey Medical Center, Hershey, Pennsylvania 17033, USA.
Jong-in HahmDepartment of Chemistry, Georgetown University, 37th & O Sts. NW., Washington, DC 20057, USA. jh583@georgetown.edu.
Georgetown University · USPenn State Milton S. Hershey Medical Center · US

Funding

ZnO Nanorod-based Early Biomarker Screening for Acute Kidney InjuryR01DK088016 · NIDDK · GEORGETOWN UNIVERSITY · PI HAHM, JONG-IN · 2010 to 2014
$1.6M
NIDDK NIH HHS 1R01DK088016NIDDK NIH HHS R01 DK088016
6 · The paper itself

Abstract

Determining ultratrace amounts of protein biomarkers in patient samples in a straightforward and quantitative manner is extremely important for early disease diagnosis and treatment. Here, we successfully demonstrate the novel use of zinc oxide nanorods (ZnO NRs) in the ultrasensitive and quantitative detection of two acute kidney injury (AKI)-related protein biomarkers, tumor necrosis factor (TNF)-α and interleukin (IL)-8, directly from patient samples. We first validate the ZnO NRs-based IL-8 results via comparison with those obtained from using a conventional enzyme-linked immunosorbent method in samples from 38 individuals. We further assess the full detection capability of the ZnO NRs-based technique by quantifying TNF-α, whose levels in human urine are often below the detection limits of conventional methods. Using the ZnO NR platforms, we determine the TNF-α concentrations of all 46 patient samples tested, down to the fg per mL level. Subsequently, we screen for TNF-α levels in approximately 50 additional samples collected from different patient groups in order to demonstrate a potential use of the ZnO NRs-based assay in assessing cytokine levels useful for further clinical monitoring. Our research efforts demonstrate that ZnO NRs can be straightforwardly employed in the rapid, ultrasensitive, quantitative, and simultaneous detection of multiple AKI-related biomarkers directly in patient urine samples, providing an unparalleled detection capability beyond those of conventional analysis methods. Additional key advantages of the ZnO NRs-based approach include a fast detection speed, low-volume assay condition, multiplexing ability, and easy automation/integration capability to existing fluorescence instrumentation. Therefore, we anticipate that our ZnO NRs-based detection method will be highly beneficial for overcoming the frequent challenges in early biomarker development and treatment assessment, pertaining to the facile and ultrasensitive quantification of hard-to-trace biomolecules.

Indexed as

Enzyme-Linked Immunosorbent AssayAcute Kidney InjuryBiomarkersHumansInterleukin-8Microscopy, Electron, ScanningNanotubesTumor Necrosis Factor-alphaZinc OxideBiomarkersInterleukin-8Tumor Necrosis Factor-alphaZinc Oxide

Identifiers

PMID26846189
PMCPMC4760885
OpenAlexW2255299594

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.